2011
RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer
Yan C, Kim Y, Ha Y, Kim I, Kim Y, Yun S, Moon S, Bae S, Kim W. RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer. Journal Of Surgical Oncology 2011, 105: 425-430. PMID: 22311819, DOI: 10.1002/jso.22087.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCarcinoma in SituCarcinoma, Transitional CellChildCore Binding Factor Alpha 3 SubunitDisease ProgressionDNA MethylationDNA, NeoplasmFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPolymerase Chain ReactionPrognosisPromoter Regions, GeneticSurvival RateUrinary Bladder NeoplasmsYoung AdultConceptsDisease progressionRUNX3 methylation statusRUNX3 methylationTumor stageBladder cancerTumor gradeNMIBC progressionInvasive bladder cancer patientsWorse progression-free survivalProgression-free survivalInvasive bladder cancerPoor clinical outcomeKaplan-Meier estimatesBladder cancer patientsMethylation statusNumber of tumorsHypermethylation of RUNX3Methylation-specific polymerase chain reactionNMIBC samplesAdvanced diseaseClinical outcomesClinicopathological characteristicsIndependent predictorsCancer patientsG3 tumors
2010
Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: A novel approach using peptide nucleic acid-mediated, real-time PCR clamping
Kim E, Yan C, Ha Y, Jeong P, Kim I, Moon S, Choi Y, Kim W. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: A novel approach using peptide nucleic acid-mediated, real-time PCR clamping. Urologic Oncology Seminars And Original Investigations 2010, 30: 673-679. PMID: 20884250, DOI: 10.1016/j.urolonc.2010.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorDNA GlycosylasesFemaleGene FrequencyGenotypeHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMusclesNeoplasm GradingNeoplasm InvasivenessNeoplasm StagingPeptide Nucleic AcidsPolymerase Chain ReactionPolymorphism, GeneticPrognosisProportional Hazards ModelsUrinary Bladder NeoplasmsConceptsMuscle-invasive bladder cancerReal-time PCR clampingInvasive bladder cancerBladder cancerHOGG1 genotypeHOGG1 codon 326 genotypesMultivariate Cox regression analysisHOGG1 codon 326Cancer-specific survivalCox regression analysisPrognostic genetic markersPCR clampingSpecific survivalSurvival benefitClinicopathologic characteristicsBC patientsPrognostic indicatorTumor gradePrognostic markerClinical dataProtective effectCancerPatientsDNA damage repair mechanismsCodon 326
2004
Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1
Kim I, Lee D, Lee D, Kim W, Kim M, Morton R, Lerner S, Kim S. Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1. Cancer Research 2004, 64: 7355-7360. PMID: 15492256, DOI: 10.1158/0008-5472.can-04-0154.Peer-Reviewed Original ResearchConceptsTSU-Pr1Cell line TSU-Pr1BMP-RIITumor growthBladder transitional cell carcinoma cellsHuman bladder cancer cell linesCell linesTransitional cell carcinoma cellsBladder cancer cell linesBone morphogenetic protein receptor type II (BMPR2) expressionBone morphogenetic proteinTSU-Pr1 cellsBladder TCC tissuesGrowth inhibitory effectsCancer cell linesBladder specimensType II expressionBladder TCCTumor gradeTransitional epitheliumClinical observationsTCC tissuesMalignant cellsSignificant associationBMP-RIA
1996
Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues.
Kim I, Ahn H, Zelner D, Shaw J, Lang S, Kato M, Oefelein M, Miyazono K, Nemeth J, Kozlowski J, Lee C. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clinical Cancer Research 1996, 2: 1255-61. PMID: 9816295.Peer-Reviewed Original ResearchMeSH KeywordsActivin Receptors, Type IAnimalsAntibody SpecificityHumansImmunohistochemistryMaleProstatic NeoplasmsProtein Serine-Threonine KinasesRabbitsReceptor, Transforming Growth Factor-beta Type IReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaTumor Cells, CulturedConceptsType II receptorHuman prostate cancer tissuesProstate cancer tissuesII receptorsProstate cancer cellsLoss of expressionTumor gradeTGF-beta receptorsCancer tissuesProstate tissueTGF-beta1 type IProstate cancer cell growthMalignant human prostate tissueType ICancer cellsHuman prostate cancer cellsGrowth factor-beta type IProstate cancer casesHuman prostate cancerBenign prostate tissueCancer cell growthHuman prostate tissueTGF-beta type IGrowth factor beta1Benign human prostate